DNA switch discovery reveals new mechanism that may help slow breast cancer growth

Researchers at Adelaide University have discovered a DNA enhancer called HRRINT3 that helps the androgen receptor suppress the growth of ER+ breast cancer cells. This finding provides new insights into potential therapeutic targets for the most common form of breast cancer.
Why it matters
This discovery could lead to more effective treatments for ER+ breast cancer, particularly for patients who have developed resistance to traditional hormone therapies.
R esearchers at Adelaide University have identified a small regulatory section of DNA that helps the body limit the growth of the most common form of breast cancer, offering new insight into how future treatments could be developed.
The discovery focuses on oestrogen receptor-positive (ER+) breast cancer, which accounts for up to 80 per cent of breast cancer cases. These cancers are driven by the hormone oestrogen and can become difficult to treat when patients stop responding to hormone therapies.
Previous research has suggested that the androgen receptor, another hormone receptor, can act as a tumour suppressor in ER+ breast cancer. Activating this receptor has been investigated as a potential treatment approach, although the precise mechanisms behind its effects have not been fully understood.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in